-- Scott Roberts
TUESDAY, Dec. 14 (HealthDay News) -- The U.S. Food and Drug
Administration has approved a new once-daily dose for Prezista
(darunavir), combined with ritonavir to treat people infected with
HIV-1, a strain of the virus that causes AIDS.
In a news release, drug maker Tibotec Therapeutics said the
approval was meant for adults who hadn't shown resistance to
darunavir, the drug's active ingredient.
People with chronic liver disease including hepatitis or
cirrhosis should be carefully monitored while taking Prezista, the
company said. They also should be watched for signs of a severe
skin reaction, which could include severe rash accompanied by
fever, fatigue, muscle or joint pain, or blisters.
Prezista does not "cure" HIV-1 or AIDS, and will not prevent
transmitting the infection to others, the drug maker stressed.
To learn more about antiviral drugs used to treat HIV infection,
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.